Our Pipeline
Our company grows out of the research of co-founder Dr. Michael R. Rose, professor of evolutionary biology at the University of California, Irvine (). This research applies quantitative genetics, experimental evolution, and genome-wide sequencing to the problem of aging. Over the last few decades, we have been working on the development of faster and more powerful ways to develop pharmaceuticals for chronic disorders of aging.
UNIQUE ADVANTAGES
1. World class genomics expertise
We have been publishing world-class genomics since 2010. Our particular focus has been parsing entire genomes for the key determinants of aging and its associated chronic diseases.
We have been publishing world-class genomics since 2010. Our particular focus has been parsing entire genomes for the key determinants of aging and its associated chronic diseases.
2. Genomically differentiated animal populations: UCI Drosophila
Our key resource is a large collection of Drosophila populations that we have evolved to improve aging and chronic disease. These populations are not inbred mutants. Instead, like humans, they are outbred and physiologically robust. We exclusively license them from the University of California.
3. Genomic insights into chronic diseases
We have developed new statistical approaches to determining the most important genomic sites and pathways underlying chronic diseases. With our animal resources and our genomic information, we have great inferential power for determining the biological foundations of chronic diseases, as well as for drug discovery.
Our key resource is a large collection of Drosophila populations that we have evolved to improve aging and chronic disease. These populations are not inbred mutants. Instead, like humans, they are outbred and physiologically robust. We exclusively license them from the University of California.
3. Genomic insights into chronic diseases
We have developed new statistical approaches to determining the most important genomic sites and pathways underlying chronic diseases. With our animal resources and our genomic information, we have great inferential power for determining the biological foundations of chronic diseases, as well as for drug discovery.
Linked Publications
Four steps toward the control of aging following the example of infectious disease
In this publication, we give our view of prospects for the control of aging. We believe that aging will be definitively controlled by the end of the 21st Century, in part because of our work on the foundations of aging. But we are not optimistic that a complete technological solution will be developed immediately. Instead, we are focused on bridge strategies for ameliorating chronic diseases of aging before science has a completely worked out understanding of aging.
The great evolutionary divide: Two genomic systems biologies of aging
One of the biggest problems in aging research, both scientific and biomedical, is the common failure to understand that the evolutionary genetics of aging come in two flavors. The first is aging among species that generally lack sexual reproduction. The Second is aging among species that regularly have sexual reproduction. We are members of the second kind of species, not the first. But much of the genetic research on aging is now done with species of the first kind. Our company focuses exclusively on organisms and methods that are appropriate to species like humans.
Rapid divergence and convergence of life-history in experimentally evolved Drosophila melanogaster
This publication presents some of our Drosophila populations that have radically different patterns of aging. These populations provide a powerful system for the study of the genomics of aging versus non-aging.
Genomics of parallel experimental evolution in Drosophila
Here we analyze the genomic foundations of delayed aging. We have found hundreds of sites involved in aging, distributed widely across the genome. Now that we know these sites, we start with this knowledge underpinning our development of candidate pharmaceuticals.
Four steps toward the control of aging following the example of infectious disease
In this publication, we give our view of prospects for the control of aging. We believe that aging will be definitively controlled by the end of the 21st Century, in part because of our work on the foundations of aging. But we are not optimistic that a complete technological solution will be developed immediately. Instead, we are focused on bridge strategies for ameliorating chronic diseases of aging before science has a completely worked out understanding of aging.
The great evolutionary divide: Two genomic systems biologies of aging
One of the biggest problems in aging research, both scientific and biomedical, is the common failure to understand that the evolutionary genetics of aging come in two flavors. The first is aging among species that generally lack sexual reproduction. The Second is aging among species that regularly have sexual reproduction. We are members of the second kind of species, not the first. But much of the genetic research on aging is now done with species of the first kind. Our company focuses exclusively on organisms and methods that are appropriate to species like humans.
Rapid divergence and convergence of life-history in experimentally evolved Drosophila melanogaster
This publication presents some of our Drosophila populations that have radically different patterns of aging. These populations provide a powerful system for the study of the genomics of aging versus non-aging.
Genomics of parallel experimental evolution in Drosophila
Here we analyze the genomic foundations of delayed aging. We have found hundreds of sites involved in aging, distributed widely across the genome. Now that we know these sites, we start with this knowledge underpinning our development of candidate pharmaceuticals.